Cogent Biosciences (COGT) AI Stock Analysis

• Market Cap: $5.62B
• Dividend Yield: N/A
• Average Volume (3M): 1.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: 4.32%
• Country: US
• Employees: 205
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.61
• Shares Outstanding: 162,308,820
• 10 Day Avg. Volume: 2,043,280
• 30 Day Avg. Volume: 1,693,953
• PEG Ratio: -2.00
• Price to Book (P/B): 3.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.03
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.38K
• Enterprise Value/Ebitda: -16.67
• 1Y Price Target: $52.55
• Price Target Upside: 52.89% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -2.12
• Revenue Forecast (FY): $17.81M

• Rating: 49 Neutral
• Price Target: $34.00 ▼(-1.08% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held down primarily by development-stage financials (near-zero revenue, widening losses, and worsening cash burn) and limited valuation support (negative P/E, no dividend). Offsetting factors include positive trial results that could improve future fundamentals and a mixed technical picture with near-term softness but longer-term trend support.

Positive Factors

Clinical trial progress

Robust trial data and an identified FDA NDA pathway for bezuclastinib materially de-risk the lead program. Clinical success directly improves the firm's long-term commercial prospects, raises the chance of partner interest or approval-driven revenue, and strengthens strategic optionality over the next several quarters.

Stronger equity base

A substantially larger equity base lengthens runway and reduces immediate dilution risk, allowing continued R&D investment across programs. This capital buffer improves financial flexibility for clinical milestones and potential commercial launch preparations, supporting durable operations through development inflection points.

Precision-targeted pipeline

A focused, biomarker-driven small-molecule approach targets genetically defined diseases, improving trial design and patient selection. This structural strategy can raise trial success odds, enable premium pricing and platform leverage across indications, sustaining competitive advantage as programs advance.

Negative Factors

No commercial revenue

The company remains pre-revenue with no commercial sales, meaning fundamentals depend entirely on pipeline progress and financing. Absent product approval or licensing, lack of operating income is a persistent weakness that forces reliance on markets or partners for funding and delays self-sustaining cash generation.

Widening cash burn

Accelerating negative free cash flow signals growing runway pressure and greater need for external financing. This structural cash burn increases dilution risk, constrains strategic choices, and raises the probability of funding-driven setbacks unless offset by approvals, partnerships, or capital raises.

Rising leverage

Material increase in debt and leverage elevates fixed obligations, interest exposure and refinancing risk. Higher leverage reduces flexibility to invest in programs and raises the consequences of any revenue shortfall, creating a lasting funding and covenant risk until deleveraging or profitable operations occur.

Cogent Biosciences Business Overview & Revenue Model

Company Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

null

Cogent Biosciences Financial Statement Overview

Summary

Financials are very weak: revenue is essentially zero (2021–2025), losses have widened materially (net loss about -$72M in 2021 to about -$329M in 2025), and free cash flow burn has deepened (about -$60M to about -$266M). The main offset is a much larger 2025 equity base, but leverage increased sharply with debt rising to about $239M, elevating financing risk.

Income Statement

The income statement remains very weak: revenue is essentially zero in 2021–2025 (annual reports), while losses have expanded materially (net loss worsening from about $72M in 2021 to about $329M in 2025). Profitability is structurally negative, reflecting a business still in heavy investment mode with no meaningful commercial scale yet, and the loss trajectory is moving in the wrong direction.

Balance Sheet

The balance sheet is mixed but comparatively more stable. Equity has increased sharply (from roughly $256M in 2024 to about $636M in 2025), providing a larger capital base. However, debt rose significantly in 2025 (to about $239M), lifting leverage (debt-to-equity moved from ~0.07 in 2024 to ~0.38 in 2025). Returns on shareholders’ capital remain deeply negative due to sizable losses.

Cash Flow

Cash flow is pressured by ongoing cash burn. Operating cash flow and free cash flow are consistently negative and have deteriorated in absolute terms (free cash flow from about -$60M in 2021 to about -$266M in 2025). A positive free cash flow growth figure in 2025 is not indicative of strength given free cash flow is still meaningfully negative, and cash generation is not yet covering the business’s cost structure.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-4.62M	0.00	0.00	0.00	0.00
EBITDA	-328.74M	-271.59M	-204.54M	-141.96M	-73.56M
Net Income	-328.94M	-255.86M	-192.41M	-140.24M	-72.27M
Balance Sheet
Total Assets	937.61M	327.90M	313.44M	300.81M	232.09M
Cash, Cash Equivalents and Short-Term Investments	900.76M	287.08M	265.71M	259.28M	219.68M
Total Debt	253.15M	17.47M	18.85M	19.65M	3.15M
Total Liabilities	301.24M	71.61M	55.63M	45.08M	17.91M
Stockholders Equity	636.37M	256.29M	257.80M	255.74M	214.18M
Cash Flow
Free Cash Flow	-266.00M	-208.36M	-156.42M	-125.50M	-60.48M
Operating Cash Flow	-264.44M	-207.79M	-153.62M	-118.64M	-58.76M
Investing Cash Flow	-399.53M	38.28M	-97.82M	-124.72M	-1.72M
Financing Cash Flow	878.23M	214.45M	163.54M	163.56M	37.98M

Cogent Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 34.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Negative. The current price of 34.37 is below the 20-day moving average (MA) of 37.12, below the 50-day MA of 37.24, and above the 200-day MA of 23.13, indicating a neutral trend. The MACD of -0.73 indicates Positive momentum. The RSI at 38.14 is Neutral, neither overbought nor oversold. The STOCH value of 33.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COGT.

Cogent Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	69 Neutral	$1.61B	13.56	19.84%	―	21.13%	50.86%
BEAM	54 Neutral	$2.56B	-34.27	-7.31%	―	-84.07%	-157.71%
IMCR	53 Neutral	$1.52B	-19.61	-6.93%	―	27.51%	38.72%
IDYA	52 Neutral	$2.86B	-26.90	-11.10%	―	5376.27%	20.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COGT	49 Neutral	$5.62B	-7.30	-100.22%	―	―	4.32%
IRON	43 Neutral	$2.26B	-13.21	-32.80%	―	―	-34.96%